Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

James Cheng-Chung WeiTae-Hwan KimMitsumasa KishimotoNaoki OgusuHaeyoun JeongShigeto KobayashiKurisu TadaMitsumasa KishimotoKou KatayamaAtsuo TaniguchiYohei SetoMitsuhiro MoritaKazuhiro HattaTetsuya TomitaNobuo NegoroHitoshi GotoShigeyoshi TsujiNorikazu MurataKiyoshi MatsuiMasahiro YamamuraHiroaki DobashiJunichi FukushiSatoshi IkemuraAkira MaeyamaMitsuyo KinjoYukitaka UekiEishi UechiTatsuya AtsumiHideto KamedaYoshinori TaniguchiSei MuraokaMasanobu OishiSeung Jae HongWon ParkShin Seok LeeChang Hee SuhSeong Wook KangTae-Hwan KimJung Yoon ChoeJi Hyeon JuJin Kyun ParkSeung-Geun LeeYun Jong LeeSang-Heon LeeCheng Chung WeiTien Tsai ChengWen Chan TsaiChung Ming HuangHsin Hua ChenDer-Yuan ChenMeng Yu WengShue Fen LuoKun Hung ChenLing Jung YenCheng Han WuHsiang Cheng Chen2026-01-302026-01-302021-0810.1136/annrheumdis-2020-219406https://scholars.csmu.edu.tw/handle/123456789/4226[SDGs]SDG3Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trialjournal-article